CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Julio Bobes

OPENALEX: A5083202579↗ORCID: 0000-0003-2187-4033↗

Affiliations

Organizations

Centro de Investigación Biomédica en Red de Salud Mentalauthorship · ES Gobierno del Principado de Asturiasauthorship · ES Instituto de Investigación Sanitaria del Principado de Asturiasauthorship · ES Instituto de Salud Carlos IIIauthorship · ES Universidad de Oviedoauthorship · ES Universidade Cidade de São Pauloauthorship · BR Universidade de São Pauloauthorship · BR Universitat de Barcelonaauthorship · ES

Public evidence

10 connected articles

Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.2024 · Europe PMC The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMC Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open Access Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.2021 · PubMed Central Open Access The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Julio Bobes - Medical Cannabis Research Engine